After decades of halting progress, recent large genome-wide association studies (GWAS) are finally shining light on the genetic architecture of schizophrenia. The picture emerging is one of sobering complexity, involving large numbers of risk alleles across the entire allelic spectrum. The aims of this article are to summarize the key genetic findings to date and to compare and contrast methods for identifying additional risk alleles, including GWAS, targeted genotyping and sequencing. A further aim is to consider the challenges and opportunities involved in determining the functional basis of genetic associations, for instance using functional genomics, cellular models, animal models and imaging genetics. We conclude that diverse approaches will be required to identify and functionally characterize the full spectrum of risk variants for schizophrenia. These efforts should adhere to the stringent standards of statistical association developed for GWAS and are likely to entail very large sample sizes. Nonetheless, now more than any previous time, there are reasons for optimism and the ultimate goal of personalized interventions and therapeutics, although still distant, no longer seems unattainable.
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Lifetime prevalence for established illness is B0.72%
8 and the suicide rate is B7%, the majority occurring in the first 3 years after onset. 9 Only a minority (o14%) experience sustained recovery within the first 5 years of illness 10 and another 16% later in the illness. 11 Current treatments have limited efficacy (80% relapse rates) 10 and financial costs are high (for example, E 94 billion for psychotic disorders in Europe, 2010), 12 with attendant medical complications (obesity, nicotine dependence, metabolic syndrome and premature mortality), low employment 13 and substantial homelessness. 14 The disorder ranks ninth in the global burden of illness, and ranks fifth (males) and sixth (females) in the leading global causes of years lost because of disability. 15 Despite the magnitude of its disease burden, the aetiology of schizophrenia remains poorly understood. The prevailing hypothesis is that schizophrenia is a neurodevelopmental disorder, 16--18 but the underlying molecular and cellular mechanisms remain a mystery. Diverse aetiological clues, including family history, early life adversity, urban upbringing, migrant status, cannabis use and a variety of pre/perinatal factors, 19 have emerged from a large body of epidemiological studies. 20 By far the most compelling of these is family history, recognized for almost a century since Kraepelin observed 'dementia praecox not at all infrequently is familial, often appearing in brothers and sisters'. 21 Decades of family, twin and adoption studies have established high heritability (81%, confidence interval: 73--90%), 22, 23 which has compelled the search for genetic variation contributing to disease.
THE PRE-GWAS ERA
Before the development of genome-wide association study (GWAS) methodology, genetic studies of schizophrenia relied on karyotyping, linkage studies and candidate gene association studies. Two of the best-known chromosomal rearrangements are large deletions on chromosome 22q11.2 and a balanced chromosomal translocation t(1:11) (q43,q21) that led to the discovery of the DISC1 (disrupted-in-schizophrenia 1) gene. The chromosome 22q11.2 deletion syndrome (22q11.2DS) occurs in 1 in 2000--4000 live births. 24, 25 Most carriers of the 22q11.2DS have either a 3 or 1.5 Mb deletion, affecting between 30 and 60 primarily brain-expressed genes. Unsurprisingly, this syndrome displays extensive phenotypic heterogeneity including a range of physical manifestations, cognitive impairments and behavioural disturbances. 25 One example is the velocardiofacial syndrome (palatal dysfunction, ventricular septal defects, dysmorphic facies and learning disabilities), 26 the syndrome most frequently reported as having both the deletion (85--100%) and psychosis, in particular schizophrenia (up to 30%). 27--29 Moreover, 22q11.2DS occurs more frequently in schizophrenia than in the general population, 30 and there does not appear to be any significant clinical differences in schizophrenia with or without 22q11.2. 31 Support for this locus has strengthened with the application of GWAS methodology and it is now widely accepted as the most robust association in schizophrenia (see below). The chromosomal translocation involving DISC1 and a non-coding RNA named DISC2 (ref. 32) was first identified in a fourgenerational Scottish pedigree 33 in which the proband had severe conduct disorder. 34 The translocation is strongly associated with psychiatric disorders in this pedigree, including recurrent major depression, bipolar disorder and schizophrenia, with strongest statistical support for a broad, cross-disorder clinical phenotype. 35 A large body of functional work motivated by the initial discovery supports an important role for DISC1 in neurodevelopment, 36 but statistical support from linkage and association studies in schizophrenia is lacking in populations other than the focal family. 37, 38 Linkage analysis assesses the co-segregation of genetic loci with disease in families. This strategy has been very successful for Mendelian traits, but less so for complex diseases. In schizophrenia, over 30 genome-wide linkage analyses have been conducted, and although some have reported genome-wide significant findings 39--42 no locus has consistently replicated across studies. In the largest schizophrenia linkage meta-analysis to date, involving 32 independent genome-wide linkage scans (3255 pedigrees; 7413 genotyped schizophrenia/schizoaffective cases) no loci surpassing genome-wide significance were identified. 43 The limited success of linkage may be a consequence of the involvement of many genes in schizophrenia and the expected rarity of mutations with large effect size.
In contrast to linkage, candidate gene association studies aim to identify commonly occurring variants of small effect. More than 1000 studies of candidate schizophrenia genes have been conducted, their candidature being based primarily on location in linkage regions or near cytogenetic abnormalities, or on psychopharmacological hypotheses regarding monoaminergic receptor genes. Results from these studies are generally inconsistent, and with hindsight it is clear that they have limited power because of small sample size and sparse marker density. Systematic meta-analyses of genetic variants that had been studied in at least four independent case--control samples (118 variants from 52 genes) revealed a 'strong' degree of epidemiological credibility for four genes (DRD1, DTNBP1, MTHFR, TPH1; 44 www.szgene.org/), although the ranking of these genes has since changed. More recently, a pathway analysis observed no enrichment of smaller P-values in hypothesis-driven candidate genes in the International Schizophrenia Consortium (ISC) GWAS, implying that these genes do not harbour commonly occurring disease-related genetic variants. 38 It remains to be seen whether rare alleles of moderate to large effect will be identified in these genes.
THE GWAS ERA: SHINING LIGHT ON THE SPECTRUM OF ALLELIC VARIATION IN SCHIZOPHRENIA
In contrast to linkage and candidate gene studies, GWAS has been successful for schizophrenia, as it has across the breadth of human complex disease. 45, 46 GWAS methodology has been facilitated by technological advances that enable the simultaneous and cost-effective analysis of large numbers of genetic markers (that is, up to 5 million) that tag a high proportion of all common single nucleotide polymorphisms (SNPs) in the human genome. Although designed primarily to identify common small effect alleles hypothesized under the common disease common variant hypothesis, data from GWAS arrays can also be used to identify rare submicroscopic chromosomal deletions and duplications known as copy number variants, or CNVs. Recent years have seen a spate of reports identifying common, polygenic and rare variants in schizophrenia, hinting at a large number of risk alleles across the entire allelic spectrum.
Common variation
The first GWAS for schizophrenia were reported in 2006--2007. 47, 48 These and other early studies 49--52 failed to identify loci surpassing modern standards for genome-wide significance (Po5 Â 10 À8 ), presumably because sample sizes were inadequate for the effect sizes that we now know are typical of common variants in complex neuropsychiatric disorders. The community has since coalesced into large international consortia with impressive results: the number of studies (including meta-analyses) reporting SNPs with genome-wide support has risen to 9 (refs 53--61) (Table 1) , and the total number of genome-wide significant loci has grown to 12, some of which include evidence for multiple independent associations (for example, 10q24.3, 11q24.2, 18q21.2). Additionally, four other loci have been identified in joint analyses of schizophrenia and bipolar disorder, 57 ,61 consistent with clinical and epidemiological evidence for shared genetic aetiology between these disorders (see below). As for other complex diseases, the identified risk alleles are common (majority 40.3) and confer small increases in risk (odds ratios mostly o1.2; Table 1 ). The largest study to date, by the Psychiatric GWAS Consortium (PGC; N ¼ 51 695), 57 identified 10 independent SNPs in eight loci (Table 1) , five of which were novel (1p21.3, 2q32.3, 8p23.2, 8q21.3 and 10q24.3). The strongest new finding was within an intron of the primary transcript of MIR137, a microRNA that has an important role in the regulation of neuronal maturation and adult neurogenesis. 62, 63 Interestingly, four other loci with genome-wide support in the same GWAS, or in joint analyses of schizophrenia and bipolar disorder (TCF4, CSMD1, CACNA1A and C10orf26), contain predicted MIR137 target sites, consistent with a possible MIR137-related mechanism in the aetiology of schizophrenia. 57 The strongest PGC hit, and the schizophrenia locus with most consistent support, is a 5.5 Mb region spanning the extended major histocompatibility complex at 6p21.3-p22.1 (Table 1) , a highly polymorphic, gene-dense region that has a central role in development of host defence and immunity. Initially identified in Europeans, this locus has now been identified in Han Chinese, 60 and finds more modest support in Japanese. 64 There is some indication that susceptibility variants in Europeans and Chinese represent different loci, although strong and complex linkage disequilibrium in this region creates significant challenges for resolving causal variants underlying associations. A second locus attracting support across both European 56 and Chinese 60 ancestral groups is 11p11.2; these associations appear to be independent, being separated by B1.7 Mb.
Polygenic variation
Common SNPs surpassing genome-wide significance in schizophrenia (Po5 Â 10 À8 ) explain very little of the variance in liability, either individually (o0.1%) or collectively (B2--3%). 65 This has led to a preoccupation with 'missing heritability' and a polarized debate about the relative importance of common and rare genetic variation in schizophrenia. 66, 67 Although this is still an
The emerging spectrum of allelic variation in schizophrenia BJ Mowry and J Gratten By using simulations they were able to show that the proportion of heritability explained was probably much larger, about onethird of the total, implying that in addition to the handful of genome-wide significant SNPs described above, there must be many (possibly thousands) more with individual effects too small to achieve statistical significance. This result has since been replicated in the PGC schizophrenia GWAS, 57 in a non-European GWAS 64 and in a family-based GWAS. 68 The latter study effectively rules out the possibility that the ISC finding is due to population stratification. Nonetheless, some have questioned the validity of the ISC's approach, 69, 70 maintaining instead that the majority of genetic risk will be explained by rare, highly penetrant variants. Similarly, Dickson et al. 70 have proposed that many common loci identified by GWAS may be explained by 'synthetic associations' involving multiple rare variants. The importance of synthetic associations is a subject of debate, 71, 72 but further evidence for an important contribution from common variation in schizophrenia has been provided by recent work 73 using an independent method 74 that is not vulnerable to the same criticisms as the ISC's approach. This analysis, using all SNPs in a large schizophrenia GWAS data set, estimated that 22% of the total liability, approximately one-third of the genetic liability, could be explained by SNPs on commercial genotyping arrays. 73 This result is consistent with the ISC's estimate for the role of common variation and suggests that many additional common variants are yet to be discovered.
Rare and de novo structural variation Structural genomic variants that increase risk of schizophrenia have long been appreciated on the basis of cytogenetic studies, such as those identifying large recurrent deletions in chromosome 22q11.2. 27, 29, 30 More recently, data from GWAS and comparative genome hybridization arrays have facilitated genome-wide screens for CNVs associated with elevated risk of disease. Three major findings have emerged from these studies. First, there is evidence for a modest increase in the burden of rare (o1%) and large (4100 kb) CNVs in schizophrenia cases compared with controls. 75--77 Second, de novo CNVs are associated with higher risk of disease. 78--80 Third, specific CNVs have now been identified that confer substantial increases in risk of schizophrenia: 75--77,81--86 at the time of writing, deletions and duplications at 10 loci had been replicated (Table 2 ). These CNVs are at low frequency in the general population (majority o0.1%) and are associated with substantially higher risks (odds ratios 2.7 to 426) than common SNPs, although none have yet been identified that are necessary and sufficient to cause disease. A majority of CNVs that have been identified are large (4100 kb) and span multiple genes. Exceptions include deletions in 2p16.3, which disrupt exons of the NRXN1 gene, and duplications in 7q36.3, which disrupt the VIPR2 gene. For some loci (for example, 3q29) both deletions and duplications are associated with increased risk of schizophrenia. Studies involving parents and offspring suggest that a high proportion of CNVs at identified schizophrenia loci are de novo in the individuals in which they occur (for example, 480% of deletions in 3q29 and 22q11.2). 79, 87 This is consistent with evidence for reduced fecundity in schizophrenia 88 and suggests that deleterious CNVs are maintained in the population by recurrent mutation in spite of selection. 87, 89 The mutation rate at known CNVs is substantially higher than the human nucleotide mutation rate, presumably The emerging spectrum of allelic variation in schizophrenia BJ Mowry and J Gratten because many are flanked by segmental duplications that are known to mediate genomic deletions and duplications via nonallelic homologous recombination. 86 This fact and the limited resolution of current generation array-based CNV detection platforms, 90 implies that many additional CNVs are likely to exist for schizophrenia.
Rare and de novo sequence variation Rare sequence variants, unlike rare CNVs, are not amenable to discovery using GWAS or comparative genome hybridization array data and must instead be identified by sequencing. Although there is great interest in the use of sequencing to identify rare variants in schizophrenia, such studies are in their infancy. The majority that have been published to date have focused on the role of de novo mutations in protein-coding genes, based on the idea that disease prevalence is maintained by de novo mutation across many genes in spite of negative selection. 91 The benefit of this approach is that whereas thousands of inherited rare variants are present in the average exome (the set of all coding exons), fewer than one de novo missense or nonsense mutation is expected per father--mother--child trio. 92 Consequently, the disruption of the same gene by de novo mutations in multiple unrelated affected individuals is unlikely to be a chance occurrence. 93 Two whole exome sequencing studies 94, 95 and a handful of hypothesis-driven candidate gene studies 96--104 have been published. Key reported findings from the exome studies include evidence for an elevated exonic de novo mutation rate in schizophrenia, 94 consistent with an earlier report based on B400 synapse genes, 97 and an excess of putatively damaging missense de novo mutations in schizophrenia cases compared with controls. 95 These are interesting results that support an important role for de novo mutations in neuropsychiatric disease. However, sample sizes are modest and no study has yet identified single genes that were disrupted in multiple probands. Published findings of putatively functional variants in candidate genes are descriptive rather than statistically supported and claims regarding the identification of functional de novo mutations should be viewed with caution. 105 Larger studies including analysis of extended pedigrees will be required to confirm the role and effect size of de novo coding mutations.
Shared genetic aetiology with other neurodevelopmental disorders Two recent strands of evidence, epidemiological and genetic, have converged to challenge the conventional diagnostic distinction between schizophrenia and bipolar disorder. A large register-based study involving over two million Swedish families demonstrated that first-degree relatives of probands with either schizophrenia or bipolar disorder were at increased risk of both these disorders because of substantial (B63%) shared additive genetic effects. 106 Genetic overlap of schizophrenia and bipolar was also supported by a Danish register-based study. 107 Consistent with these studies, recent genetic analyses have reported evidence for shared polygenic variation between these disorders, 53 and four individual loci (ANK3, CACNA1C, ITIH3-ITIH4 and ZNF804A) have achieved genome-wide significance in recent GWAS of combined schizophrenia and bipolar disorder samples (Table 1) . 57,61,108--111 Genetic evidence in the form of shared rare CNVs is also challenging the distinction between schizophrenia and other neurodevelopmental disorders, including autism, mental retardation, developmental delay and epilepsy. For example, deletions in 2p16.3 (NRXN1), 1q21.1 and 15q13.3 have all been identified in autism spectrum disorders and mental retardation (Table 2) , 112, 113 in addition to schizophrenia. Evidence for sharing of CNVs between schizophrenia and bipolar disorder is also accumulating, with several studies reporting preliminary support for established schizophrenia loci 3q29 and 16p11.2 in bipolar disorder. 78, 83, 114 The broad clinical outcomes associated with these CNVs imply that the genetic background upon which they are expressed is crucial. More generally, sharing of common SNPs or rare CNVs may be due to pleiotropy, whereby a single gene is associated with more than one distinct phenotype, 115 or to clinical overlap, exemplified by occurrence of psychosis in schizophrenia and bipolar disorder.
Risk-conferring molecular pathways A large number of risk alleles, both common and rare, are likely to exist for schizophrenia, but these are expected to cluster in a more manageable number of molecular pathways, as has been shown for height. 116 O'Dushlaine et al. 117 identified the cell adhesion molecule pathway as associated with both schizophrenia and bipolar disorder using SNP data from the ISC (N ¼ 6909) and Genetic Association Information Network (N ¼ 2729) studies. This pathway is involved in synaptic formation and normal cell signalling and includes the candidate genes NRXN1 and CNTNAP2. Further support for synaptic genes has been reported by Lips et al., 118 using the same data but a different analytic approach, and by Glessner et al., 119 on the basis of genome-wide CNV analyses. An important caveat to the latter study is that brainexpressed genes are relatively large and gene size has been shown to be a major confounder in CNV-based pathway analyses in neuropsychiatric disorders. 120 When this confounder is accounted for synapse genes (N ¼ 209) are not supported by pathway analysis of ISC CNVs, but genes involved in neuronal activity are supported. 120 Conversely, a more recent analysis by Kirov et al., 80 which is the largest to date and which also accounts for confounders such as gene size, demonstrated that de novo CNVs identified in 662 parent-case trios were significantly enriched for genes involved in the postsynaptic density, particularly members of the NMDAR postsynaptic signalling complex. Larger studies of both common and rare variation will help clarify the potential role of these and other pathways in schizophrenia.
GENETIC ARCHITECTURE COMES INTO FOCUS
The genetic architecture of schizophrenia has been the subject of protracted and polarized debate. 66, 67 The predominant views until recent times were the common disease common variant (CDCV) hypothesis, which supposes that disease is underpinned by a large number of common variants of individually small effect, and the common disease rare variant (CDRV) hypothesis, which argues for a model of extreme genetic heterogeneity involving many rare but highly penetrant mutations. 67, 69 Findings from the latest GWAS and genome-wide CNV studies make it abundantly clear that the truth lies somewhere between these two extremes and is likely to involve a spectrum of allelic variation from common to rare, as others 65, 121 have noted (Figure 1 ). The variants that have been identified have effect sizes that are roughly inversely proportional to allele frequency. 121 Although we do not yet know the strength of this relationship, it is expected because schizophrenia is known to be associated with reduced fecundity 88 and negative selection is expected to act on deleterious variants in proportion to their correlation with fitness. 122, 123 The growing evidence for an elevated de novo mutation rate in schizophrenia, both for CNVs 79 and putatively functional protein-coding point mutations, 94, 95 is also consistent with the idea that schizophrenia is maintained by a balance between mutation and selection across a large mutational target. 87, 91 In spite of this recent progress, there is still much that we do not know. For instance, the proportion of genetic liability explained by rare sequence variants is unknown, as is the relative importance of rare sequence variants compared with rare CNVs. To date, variants at intermediate frequencies (that is, between common SNPs with minor allele frequency 0.05 and rare CNVs with minor allele frequency typically o0.001) have not been identified, although it seems coincidental that this allele frequency window is yet to be systematically investigated (Figure 1 ). With regard to structural variation, we do not know to what extent inversions and translocations contribute along with CNVs, and if risk is primarily associated with large structural variants (4100 kb), or if smaller and/or more common variants are also risk conferring. With respect to the genomic context of common and rare variation underlying disease, there is remarkably little data on the relative importance of variation in protein-coding genes as opposed to regulatory elements and non-coding genes (but see Richards et al.) . 124 Finally, more data are required before we can ascertain the strength of the relationship between risk allele frequency and effect size.
STRATEGIES FOR IDENTIFYING COMMON, LOW FREQUENCY AND RARE GENETIC VARIANTS
The primary goal of schizophrenia genetics is to identify genetic variants and pathways underlying risk of the disorder. In light of the emerging evidence for a spectrum of allelic variation in schizophrenia, diverse approaches, including GWAS, dense targeted genotyping, sequencing and studies that combine these methods, will all be important priorities for establishing novel statistical associations. Figure 1 . Schematic representation of current genetic findings in schizophrenia (brown panels) in relation to prevailing genetic models of disease (green panel: CDRV, common disease rare variant hypothesis; CDCV, common disease common variant hypothesis), major genomics methodologies (orange panel: NGS, next-generation sequencing; GWAS genome-wide association studies; aCGH array-comparative genomic hybridization) and proportion of genetic variance explained (blue/purple panel). More than a dozen common alleles with small individual effects have been identified, and many more are inferred to exist on the basis of genome-wide analysis of GWAS data sets (yellow ellipse). This polygenic variation is consistent with the CDCV and may account for up to one-third of the genetic risk. Rare copy number variants (CNVs) with larger individual effects have also been identified on the basis of genome-wide analyses of GWAS and aCGH data sets (orange ellipse). These variants are more consistent with the CDRV, although to date no Mendelian mutations that are necessary and sufficient to cause disease have been identified (red panel). Similarly, no variants with intermediate allele frequency (that is, between that of common single nucleotide polymorphisms (SNPs) with minor allele frequency (MAF)X0.05 and rare CNVs with MAFo0.001) have been identified, but this region of the allelic spectrum is yet to be systematically investigated by customized genotyping and next-generation sequencing approaches. The effect size of identified risk alleles is roughly inversely proportional to allele frequency (approximated by the black curve), although the strength of this relationship is currently unknown (blue shading). Many rare variants that do not impact on risk of schizophrenia are expected to exist.
GWAS
There is widespread agreement that larger GWAS will attain the statistical power required to identify additional common SNPs that are known to exist on the basis of polygenic analyses. 53, 65, 121, 125, 126 The conflicting view that GWAS is not worth persisting with, 67, 69 which is based on the premise that most of the heritability is due to rare highly penetrant variants, appears increasingly untenable in light of the accumulating evidence for an important contribution from common variation. 126 The largest schizophrenia GWAS to date, that of the PGC (Ripke et al., 127 because of the substantial costs of clinical ascertainment and diagnosis. Nonetheless, the rate of discovery of novel loci per 1000 cases in schizophrenia is typical of other diseases, 121 and efforts are ongoing to accumulate larger samples for meta-analysis as part of the 'PGC2' collaboration. It has been estimated that a schizophrenia GWAS with 50 000 cases and 50 000 controls would have equivalent power to a study of height with 180 000 participants, 128 a recent example of which identified 180 genome-wide significant loci that clustered non-randomly in biologically plausible pathways. 116 This suggests that larger GWAS in schizophrenia are likely to identify many additional loci, thereby providing important biological leads for functional studies into disease mechanisms. For these reasons, we concur with others (for example, Sullivan) 125 that GWAS should continue to be a high priority for the field.
At the same time, it is important to note that GWAS has limitations. Most SNPs identified by GWAS are expected to be proxies for the unobserved risk-conferring variants, rather than directly functional, 45 and many occur in extended blocks of linkage disequilibrium containing multiple candidate genes and other strongly associated SNPs, as is the case for schizophrenia in the extended major histocompatibility complex region. 57 Consequently, GWAS rarely provides conclusive evidence for a single gene or causal variant and fine-mapping is an important consideration. A second limitation is that commercial genotyping arrays tag very little of the rare and low-frequency variation in the genome, which is likely to account for a substantial fraction of the two-thirds of the heritability that cannot be attributed to common SNPs. 126 Consequently, even the largest GWAS that are currently envisaged will explain only a modest proportion of the genetic liability. 116 Other approaches, including targeted genotyping and sequencing, will be required to fine-map common alleles and to expand the catalogue of identified variants to include those (other than large CNVs) at the rare end of the allelic spectrum.
Customized SNP chips One option for targeting a broader spectrum of allelic variation, and for fine-mapping existing associations, is to undertake very dense genotyping of specific loci previously implicated by GWAS in diseases with shared aetiology. An example is provided by the Immunochip, which includes all known variants (NE200 000), common and rare, in 4180 distinct genome-wide significant loci for multiple autoimmune and inflammatory diseases. 129 Early indications from a study of Crohn's disease are promising, 130 and suggest that this approach may be an efficient means of finemapping causal variants in immune diseases. Although designed for immunogenetics, the Immunochip is likely to be a valuable tool in psychiatric genetics because it includes or tags many of the SNPs in the PGC GWAS with P-values o1 Â 10
À5
. Another ongoing development is the exome chip, which aims to include a high proportion of putatively functional variants (for example, nonsynonymous, splicing and nonsense) present in a collection of B12 000 sequenced genomes and exomes (http://genome.sph.umich.edu/ wiki/Exome_Chip_Design). The aim is to provide an affordable array-based solution for screening functional coding variants of potential disease relevance. The exome chip will include 525 top GWAS SNPs for schizophrenia, and a planned extension known as the 'Psych-chip' will include B20K schizophrenia GWAS SNPs (Naomi Wray, personal communication). A major advantage of these customized chips is that consortiums can achieve very competitive pricing (for example, oUS$40/Immunochip compared with BUS$250 for standard GWAS chips) by ordering large batches of chips, making them a cost-effective solution for interrogating a broad spectrum of allelic variation in known disease loci and in protein-coding genes. Limitations include a reliance on findings from previous GWAS studies, and the fact that only a small fraction of all rare variants, including those in proteincoding genes, have been identified. For these reasons, agnostic screening for rare and low-frequency sequence variants in schizophrenia will require sequencing.
Sequencing
There is currently enormous interest in the application of nextgeneration sequencing in studies of complex disease, driven by recent technological advances that have led to stunning increases in throughput and corresponding reductions in per nucleotide costs. 131 The expectation is that rare risk alleles will exhibit larger effects than common SNPs identified by GWAS, 132 and that their identification, especially those whose functional consequences are readily interpretable (for example, in protein-coding genes), may yield commensurate insights into disease mechanisms. 133 This promise is yet to be realized in schizophrenia, or indeed any psychiatric disease, and will entail far greater challenges than the widely celebrated successes in studies of rare Mendelian disorders. 134, 135 The sequencing paradigms developed for such diseases, for instance involving small numbers of unrelated individuals with the same rare condition (for example, Miller syndrome, Roach et al.), 136 will not work for schizophrenia, because there are (to our knowledge) no known Mendelian forms. Rather, current evidence suggests that multiple genetic variants, rare, low-frequency and common, combine with environmental risk factors to form disease. Differentiating the small percentage of disease-relevant rare and low-frequency alleles from the huge number present in the typical exome (thousands) or genome (millions) 92 represents a major analytic challenge. Power to establish a genetic association is a function of the variance in liability explained, which is determined by allele frequency and effect size. As effect size is expected to be inversely proportional to risk allele frequency, 123 reflecting the role of negative selection, very large sample sizes, rivalling those for GWAS, will be required to establish statistical associations with individual sequence variants; because those with large effects are likely to be very rare, whereas low-frequency variants are likely to have more modest effect size. Collapsing methods for gene-based analysis of rare variants have been shown to be more powerful, 137, 138 but nonetheless will require large sample sizes when undertaken on an exome or genome-wide level. Such studies will entail major challenges, not least in terms of the computational resources that are required for processing, quality control and annotation of the typically very large data sets. Additionally, although sequencing costs are dropping rapidly (BUS$1000 for whole exome and BUS$4000 for whole genome at the time of writing), they remain high in comparison with genotyping (BUS$250), and we are not yet at the point where exome or genome sequencing of large case--control samples (that is, tens of thousands) is feasible. There is little doubt that this time is rapidly approaching, but presently, the optimal design for identification of rare and low-frequency variants in schizophrenia is likely to involve exome or genome sequencing in discovery samples followed by targeted genotyping (or imputation) in large independent, ethnically matched case--control cohorts. 143 Some in the schizophrenia genetics community have cautioned against unrealistic expectations from sequencing. 121 Although we concur, it is clear that DNA sequencing technologies 131 and bioinformatics tools for processing, annotating and interpreting sequence variation are maturing rapidly. 144 Studies combining sequencing with imputation and targeted genotyping appear promising, and large GWAS data sets collected by consortiums such as the PGC should enable similar studies to be performed for schizophrenia. We suggest that GWAS, targeted genotyping and sequencing will all be essential to future progress and we urge the community (and major funding bodies) to embrace them.
FUNCTIONAL CHARACTERIZATION OF GENETIC ASSOCIATIONS: OPPORTUNITIES AND CHALLENGES
Genetic variants that are robustly associated with schizophrenia provide essential biological leads for subsequent functional studies that aim to improve understanding of biological mechanisms involved in disease aetiology. It is expected that by determining how risk alleles contribute to aberrant functioning at the molecular, cellular, synaptic and neural circuitry levels, that we will ultimately gain the necessary aetiological and pathophysiological understanding to inform the development of evidencebased therapeutics.
Functional genomics Recent technological advances are providing powerful new tools for characterizing the transcriptional landscape in disease-relevant tissues (Figure 2 ). In particular, new methods for high-throughput RNA sequencing (known as RNA-seq) are enabling transcriptomewide profiling of expression level and splicing variation of coding and non-coding RNAs. 145 This data can be related to genotype at candidate SNPs in order to identify genetic variants (referred to as expression quantitative trait loci (QTL) and splicing QTL) involved in regulation of gene expression, a mechanism that is expected to explain many common risk alleles identified by GWAS. 124 This approach may also help to isolate disease genes in regions of high linkage disequilibrium containing multiple candidates. An important resource for such analyses has been generated by several recent studies that performed large-scale expression profiling in multiple brain regions and across age groups. 146, 147 Other functional genomics methods, including chromatin immunoprecipitation followed by sequencing (CHiP-seq) and bisulphite sequencing (Meth-seq), among others, are enabling genome-wide surveys of DNA--protein interactions and epigenetic modifications (respectively), thereby helping to annotate regulatory elements in the genome. 148 Integration of these data using systems biology approaches (for example, by creating protein--protein interaction networks or gene co-expression networks) will be essential for gaining understanding of which molecular pathways are disrupted in schizophrenia. 149 Despite this technical progress, functional genomic studies in complex neurodevelopmental disorders such as schizophrenia face manifold challenges (Figure 2) . A key difficulty is that the changes in gene expression or splicing (for example) that underlie many genetic associations are likely to be age, tissue and cell-type specific. 146 This imposes important constraints on functional investigations that rely on peripheral tissues such as lymphocytes 150 or on post-mortem brain samples. 151 The former is readily accessible, but only a modest proportion of genes appear to be co-expressed in blood and brain. 152 This knowledge places significant caveats on blood-based expression studies in psychiatric disorders, although lymphocyte-based expression profiling may yet be valuable for investigating immune-related hypotheses of schizophrenia aetiology, 153 and there remains substantial interest in the identification of blood-based biomarkers for schizophrenia (for example, metabolites) that may augment clinical diagnoses. 154 In contrast, post-mortem brain tissue provides a unique opportunity to perform in-depth molecular analyses not possible with living subjects, and which may not occur in peripheral tissues. 155 A major limitation of post-mortem studies is that brain samples are typically collected years or decades after disease onset, at which time expression level in cases may be more reflective of medication history than primary disease aetiology. Additionally, several other factors can confound expression levels in post-mortem brain studies, including sex, age, post-mortem interval, tissue pH and agonal state; 146 obtaining large samples that are matched for these confounders represents a significant challenge. 155 Cellular and animal models In vivo models of disease including cellular and animal models circumvent some of the difficulties presented by primary human tissues (Figure 2 ). The rapidly expanding field of induced pluripotent stem cells (iPSC) and their differentiation into neurons and glial cells, or the direct conversion of somatic cells into neurons, provides the opportunity to address the inaccessibility of the human brain by studying live patient-specific neurons, and to observe disordered molecular networks that take into account the complete genetic background of the individual. 156 As such, patient-derived neuronal cell lines may be the most appropriate and relevant cell model system for drug screening to find potential therapeutics. 157 There are now several schizophrenia iPSC reports; 158--160 Brennand et al., 159 for example, reported reduced neuronal connectivity, decreased glutamatergic receptor expression, and altered gene expression in many cyclic AMP and Wnt signalling pathways, ameliorated following antipsychotic administration. However, sample sizes are small and as with any new field a cautious approach is required. Current challenges include reproducibility, neuronal characterization and uncertainties about the correlation of expression level in cultured cells compared with primary brain neurons, particularly with respect to changes during disease onset.
Animal models provide a solution to this difficulty because they can be surveyed, at molecular, cellular and neural circuitry levels, at multiple developmental time-points and brain regions (Figure 2) . 161 They also enable the behavioural consequences of candidate mutations to be evaluated, although with the caveats that positive symptoms such as delusions and auditory hallucinations cannot be modelled in animals, and typical behavioural paradigms, such as prepulse inhibition, measures of attention and working memory tasks, although relevant to schizophrenia, are not specific to this disorder. 161 One major class of mouse models are those that aim to model specific aetiological factors such as genetic risk loci. Many such models have been developed using sophisticated genetic tool kits that enable mouse homologues of human genes to be 'knocked out' (that is, inactivated), or specific human mutations to be 'knocked in' to the mouse genome.
Common risk alleles are generally considered more difficult to model, because they have subtle effects and most are proxies for the unobserved causal variants. For this reason, the most tractable risk alleles for study using animal (and indeed cellular) models are likely to be rare CNVs associated with high risk, such as 22q11.2 and NRXN1. A number of 22q11.2 mouse models have been developed, including several that are heterozygous for the 1.5 Mb deletion, 162, 163 and which therefore most closely recapitulate the human mutation, and others involving knockouts of individual genes in the deletion region. 161 Characterizing rodents such as these may help improve our neurobiological understanding of each particular candidate. Other model organisms such as the worm, fly, bee and zebra fish provide other advantages, such as cost-effective high-throughput screening of potential therapeutic targets, rapid life cycles and easy housing. 164, 165 Limitations of animal models include the problem that knockouts or knock-ins of single loci do not reflect the polygenic architecture of human disease, 166 and the consequences of complete inactivation of genes, for instance in knockout models, may not faithfully represent the subtle effects of human risk alleles. A final caveat is that mouse models generally have a poor record in translating genetic findings into human therapeutics, 167 possibly due to human-specific differences in signalling and expression pathways. 168, 169 Neuroimaging, neurocognitive and neuroanatomical endophenotypes A parallel avenue of functional investigation of genetic associations involves studying their correlation with neuroimaging, neurocognitive and neuroanatomical intermediate phenotypes 170 in healthy 171 and affected participants (Figure 2 ). These intermediate phenotypes must be repeatable, stable (occur pre-illness onset and throughout the illness), and heritable. Many neurocognitive intermediate phenotypes have been shown to be heritable, although estimates appear to be lower than that of the clinical phenotype. 172 The evidence for heritable neuroimaging intermediate phenotypes is more mixed, with hippocampal volume reduction attracting most support. 173, 174 The endophenotyping paradigm is exemplified by studies of two GWAS-identified loci, Figure 2 . Roadmap for the identification and functional investigation of schizophrenia risk alleles. The primary goal of schizophrenia genetics is to identify genetic variants that increase risk of the disorder. In light of the growing evidence for a spectrum of allelic variation in the disorder, diverse approaches, including GWAS, customized chips and sequencing, will all be important priorities for establishing novel statistical associations. These discoveries provide the foundation for functional investigations that aim to advance understanding of disease mechanisms at the molecular, cellular, synaptic and neural circuitry levels. Major advances in sequence-based functional genomics (RNA-seq, CHiP-seq, Meth-seq) are enabling detailed profiling of expression level and transcriptional regulation. These studies can be undertaken in peripheral tissues, post-mortem brain samples, iPSC-derived neuronal cell lines or animal models, each of which has strengths and weaknesses. Integration of genetic, transcriptomic and epigenomic data using systems biology approaches has the potential to identify the key molecular pathways that are disrupted in schizophrenia. A parallel avenue of functional investigation involves the study of neuroimaging, neurocognitive and neuroanatomical correlates of confirmed risk loci in healthy and affected individuals. It is anticipated that in combination such studies will yield the necessary biological insight to facilitate personalized interventions and develop novel therapeutics. CNV, copy number variant; DLPFC, dorsolateral prefrontal cortex; DTI, diffusion tensor imaging; eQTL, expression quantitative trait locus; fMRI, functional magnetic resonance imaging; GWAS genome-wide association studies; HC, hippocampus; iPSC, induced pluripotent stem cell; miRNA, microRNA; ncRNA, non-coding RNA; PET, positron emission tomography; sMRI, structural magnetic resonance imaging; SNP, single nucleotide polymorphism.
ZNF804A
61,110 and CACNA1C. 57, 111 Neuroimaging studies of healthy carriers of ZNF804A risk allele rs1344706 exhibit changes mirroring those found in schizophrenia patients, including frontohippocampal dysconnecitivity, 175--177 larger white matter volumes and reduced grey matter volumes (for example, parahippocampal gyrus) and impaired visuomotor performance. 178 Healthy carriers of the CACNA1C risk variant (rs1006737) have been reported to show reduced hippocampal activation and connectivity during episodic memory recall, reduced activation of the subgenual anterior cingulate cortex, 179 and impaired spatial working memory that was also shown in those with schizophrenia but not bipolar disorder. 180 These 'healthy carrier' studies have the major benefit that illness confounds such as medication history can be avoided. However, current endophenotype findings are weaker than the primary genetic associations, and as in early schizophrenia GWAS, this is likely a reflection of limited sample size. Hence, their primary value lies in investigating known genetic loci, rather than discovery of novel loci underlying endophenotypic variation. In the long term, these studies together with intermediate phenotype studies of affected individuals with known CNVs, such as the 22q11 deletion syndrome, 181 may help identify more homogeneous clinical sub-types for further aetiological study. 182 Longitudinal studies of 22q11.2 children (for example) who do and do not develop psychosis may be particularly important for clarifying the trajectory from risk to disorder. 183 
PROSPECTS FOR PERSONALIZED INTERVENTIONS AND THERAPEUTICS
The ultimate goal of schizophrenia genetics is to advance aetiological understanding to the point where individuals at elevated risk can be identified before disease onset, and intervention strategies and therapeutics can be personally tailored based on understanding of underlying disease mechanisms. It is anticipated that such evidence-based therapeutics will have higher clinical efficacy and fewer side effects compared with current options. This goal remains distant, but recent genetic discoveries are providing novel candidates for therapeutic evaluation and provide the foundation for future work that may lead to accurate prediction of genetic risk.
Genetic risk prediction Predicting individuals at increased risk of disease has the potential to expedite early diagnosis and develop more effective interventions. The assessment of risk predictors in complex disease is based on the area under the receiver operator characteristic curve. The receiver operator characteristic curve is calculated from the relationship between the cumulative proportion of disease cases and the proportion of the population following ranking (from highest to lowest) according to the particular risk predictor. In schizophrenia, the current best predictor is family history, with the area under the receiver operator characteristic curve for threegeneration families equal to 0.66. 184 In principle, given sufficient knowledge of the genetic factors underlying risk of disease, it may be possible to develop genetic risk predictors that surpass family history, which has limitations, for instance because siblings are predicted to have equal risk despite genetic differences. It is important to note that this is not contingent upon discovering causal variants, because knowledge of markers that tag causal variants will suffice. By extension, the value of this approach lies not in understanding pathophysiology, but in identifying those at risk of disease. A number of studies 184--186 have addressed this question in light of the growing number of common and rare risk loci that have been identified by genome-wide analyses (see above). Wray et al. 184 demonstrated that a genetic predictor made up of alleles collectively explaining 25% of the heritability would out-perform family history (area under the curve B0.8). Currently, there is insufficient information available to construct a genetic risk score because genome-wide significant common SNPs and rare CNVs collectively explain only B2% of the genetic variance. Larger and diverse genetic studies (as outlined above) will be needed before genetic risk prediction becomes a reality.
Development of novel therapeutics Existing therapeutics, including first-and second-generation antipsychotics, have limited efficacy in many patients and pronounced side effect profiles, including tardive dyskinesia and extra-pyramidal symptoms, weight gain and metabolic syndrome, agranulocytosis, and cadiomyopathies. 187 There is thus a pressing need to discover safe, efficacious therapeutics that are based on pathophysiological mechanisms. This has proven to be an inherently complex, difficult and risky process, 188 particularly in psychiatry. 189 The main obstacles involve insufficient knowledge of the mechanisms underlying the impact of genetic variation on treatment response. Many (but not all) major pharmaceutical companies are withdrawing from traditional neurotransmitterfocused research and at least one (Novartis) is purported to be investing heavily in genetic studies as the most promising avenue of research to gain the necessary understanding of disease mechanisms. 190 Although relatively few genetic loci have been identified to date, some may provide novel drug targets. Genes mapping to CNVs may be particularly promising because of the large individual effect sizes of these loci. One such gene is the nicotinic cholinergic receptor alpha-7, CHRNA7, situated in the 15q13-q14 locus, which is strongly supported in schizophrenia on the basis of genome-wide evidence for 15q13.3 duplications, 77 as well as from linkage 191, 192 and association 193 studies. Several alpha-7 agonists are in clinical development for schizophrenia. These compounds show P50 deficit normalization in schizophrenia, fewer alpha-7 receptors in hippocampus and cortex 194 and are involved in the CHRNA7-mediated release of gamma-aminobutyric acid by hippocampal interneurons. 195 A particular alpha-7 receptor partial agonist 3-[2,4-dimethoxybenzylidene] anabaseine, appears promising in phase I and II trials; it appears to improve neurocognitive deficits 196, 197 and default network function in schizophrenia. 198 One cautionary note is the rapid desensitization in vitro, questioning its applicability as a clinically relevant drug target. 199 Another potential novel therapeutics target, also implicated by a replicated duplication (in chromosome 7q36), is VIPR2. 77, 86 This gene encodes the vasoactive intestinal peptide (VIP) receptor VPAC2, a G-protein-coupled receptor that appears to be overexpressed in patients with the duplication. Selective antagonists of VPAC2 may have therapeutic potential in these individuals. 86 CHRNA7 and VIPR2 constitute two promising leads for novel therapeutics. However, translating genetic findings into effective therapies in schizophrenia is a distal rather than proximal goal for the field and will be a defining challenge in the coming decades. 200 
CONCLUSION
The onset of large-scale genome-wide association and CNV studies has led to rapid advances in our understanding of the genetic architecture of schizophrenia. A growing number of common SNPs and rare CNVs have now been replicated, including some (for example, MIR137 and its putative targets TCF4, CSMD1 and others) that hint at possible novel aetiological mechanisms. Despite this tangible progress, identified loci collectively explain only a few percent of the genetic risk. The source of the remaining heritability has been the subject of intense debate, particularly regarding the relative importance of common and rare alleles. Like others, 65 we consider this dichotomous view to be unhelpful, because the current evidence supports the existence of a large number of risk alleles across the entire allelic spectrum. In this article, we argue that diverse approaches, including larger GWAS, targeted and customized genotyping, sequencing and combinations of these methods, will be required to identify additional risk alleles from common to rare. In all instances, large samples sizes (that is, tens of thousands) will be key in order to establish statistical significance. A second major focus of the field is functional investigation of genetic associations in order to determine how risk alleles contribute to aberrant functioning at the molecular, cellular, synaptic and neural circuitry levels. Such studies are being facilitated by rapid advances in functional genomics, cellular biology and neuroimaging, and it is anticipated that the resulting aetiological and pathophysiological understanding will inform the development of evidence-based therapeutics. Significant challenges remain and few if any genetic risk factors have been definitively functionally characterized to date. We can expect this to be a crucial rate-limiting step in the translation of genetic findings into clinical benefits. 189 
